Gene expression profiling and its practice in drug development

Current Genomics

Volumn 8, Issue 4, 2007, Pages 262-270

  Chengalvala, Murty V ^a   Chennathukuzhi, Vargheese M ^b   Johnston, Daniel S ^b   Stevis, Panayiotis E ^b   Kopf, Gregory S ^b  

^a Regulatory Operations   (United States)

^b PFIZER INC   (United States)

Author keywords

Biomarkers; Expression profiling; Microarray analysis; Pharmacogenomics; Toxicogenomics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 METHYLCHOLANTHRENE; A 277249; AROCLOR 1254; BIOLOGICAL MARKER; CIPROFIBRATE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE INHIBITOR; IRINOTECAN; PIOGLITAZONE; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; TROGLITAZONE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEPRESSION; DNA FINGERPRINTING; DNA MICROARRAY; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG INFORMATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE NUMBER; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; IMMUNOTOXICITY; LIVER TOXICITY; MICROARRAY ANALYSIS; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOGENETICS; PREDICTION; PROTEIN EXPRESSION; QUALITY CONTROL; REGULATORY MECHANISM; REPRODUCTIVE TOXICITY; REVIEW; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; TISSUE MICROARRAY; TOXICOGENETICS; TOXIN ANALYSIS; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ANIMALIA;

EID: 34547746749     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920207781386942     Document Type: Review

References (61)

1. Oeppen, J., Vaupel, J.W. DEMOGRAPHY: Enhanced: Broken Limits to Life Expectancy. Science 2002, 296: 1029-1031.
2. Janssen, P., Audit, B., Cases, I., Darzenta, N., Goldovsky, L., Kunin, V., Nuria, L-G., Manuel, P-A.J., B. P-LJ, Tsoka, S., Ouzounis, C. Beyond 100 Genomes. Genome Biol. 2003, 4: 402-505.
3. Kane, M.D., Jatkoe, T.A., Stumpf, C.R., Lu, J., Thomas, J.D., Madore, S.J. Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucl. Acids Res. 2000, 28: 4552-4557.
4. Beaucage, S.L. Strategies in the Preparation of DNA Oligonucleotide Arrays for Diagnostic Applications. Curr. Med. Chem. 2001, 8: 1213-1244.
5. Ganter, B., Tugendreich, S., Pearson, C.I., Ayanoglu, E., Baumhueter, S., Bostian, K.A., Brady, L., Browne, L.J., Calvin, J.T., Day, G-J., Breckenridge, N., Dunlea, S., Eynon, B.P., Furness, L.M., Ferng, J., Fielden, M.R., Fujimoto, S.Y., Gong, L., Hu, C., Idury, R., Judo, M.S.B., Kolaja, K.L., Lee, M.D., McSorley, C., Minor. J.M., Nair, R.V., Natsoulis, G., Nguyen, P., Nicholson, S.M., Pham, H., Roter, A.H., Sun, D., Tan, S., Thode, S., Tolley, A.M., Vladimirova, A., Yang, J., Zhou, Z., Jarnagin, K. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 2005, 119: 219-244.
6. Fielden, M.R., Eynon, B.P., Natsoulis, G., Jarnagin, K., Banas, D., Kolaja, K.L. A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity. Toxicol. Pathol. 2005, 33: 675-683.
7. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J-P., Subramanian, A., Ross, K.N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Wei, R., Carr, S.A., Lander, E.S., Golub, T.R. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science 2006, 313: 1929-1935.
8. Shaw, K.J., Morrow, B.J. Transcriptional profiling and drug discovery. Cur. Opi. Pharmacol. 2003, 3: 508-512.
9. Korkola, J.E., Blaveri, E., DeVries, S., Moore, D.H.I., Hwang, E.S., Yunn-Yi, C., Estep, A.L.H., Chew, K.L., Jensen, R.H., Waldman, F.M. Identification of a Robust Gene Signature that Predicts Breast Cancer Outcome in Independent Data Sets. BMC Cancer 2007, 11: 61-74.
10. Johnston, D.S., Bai, Y., Kopf, G.S. Utilization of Human Genome Databases in Strategies for Contraceptive Development. In: Turner TT, Hinton BT (eds.), Epididymis III: The third international conference on the epididymis. Charlottesville: The Van Doren Company; 2002, 256-270.
11. Pan, H., O'Brien, M.J., Wigglesworth, K., Eppig, J.J., Schultz, R.M. Transcript profiling during mouse oocyte development and the effect of gonadotropin priming and development in vitro. Develop. Biol. 2005, 286: 493-506.
12. Shima, J.E., McLean, D.J., McCarrey, J.R., Griswold, M.D. The Murine Testicular Transcriptome: Characterizing Gene Expression in the Testis During the Progression of Spermatogenesis. Biol. Reprod. 2004, 71: 319-330.
13. Johnston, D.S., Jelinsky, S.A., Bang, H.J., DiCandeloro, P., Wilson, E., Kopf, G.S., Turner, T.T. The Mouse Epididymal Transcriptome: Transcriptional Profiling of Segmental Gene Expression in the Epididymis. Biol. Reprod. 2005, 73: 404-413.
14. Jelinsky, S.A., Turner, T.T., Bang, H.J., Finger, J.N., Solarz, M.K., Wilson, E., Brown, E.L., Kopf, G.S., Johnston, D.S. The Rat Epididymal Transcriptome: Comparison of Segmental Gene Expression in the Rat and Mouse Epididymides. Biol. Reprod. 2007, 76: 561-570.
15. Luzzi, V.I., Holtschlag, V., Watson, M.A. Gene expression profiling of primary tumor cell populations using laser capture microdissection, RNA transcript amplification, and GeneChip microarrays. Meth. Mol. Biol. 2005, 293: 187-207.
16. Liang, W.S., Dunckley, T., Beach, T.G., Grover, A., Mastroeni, D., Walker, D.G., Caselli, R.J., Kukull, W.A., McKeel, D., Morris, J.C., Hulette, C., Schmechel, D., Alexander, G.E., Reiman, E.M., Rogers, J., Stephan, D.A. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol. Genomics 2007, 28: 311-322.
17. de Longueville, F., Atienzar, F.A., Marcq, L.,Dufrane, S., Evrard, S., Wouters, L., Leroux, F., Bertholet, V., Gerin, B., Whomsley, R., Arnould, T., Remacle, J., Canning, M. Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol. Sci. 2003, 75: 378-392.
18. Service, R.F. Pharmacogenomics. Going from genome to pill. Science 2005; 308: 1858-1860.
19. Yang, Y., Blomme, E.A, Waring, J.F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem. Biol. Interact. 2004, 150: 71-85.
20. Leighton, J.K., Brown, P., Ellis, A., Harlow, P., Harrouk, W., Pine, P.S., Robison, T., Rosario, L., Thompson, K. Workgroup report: Review of genomics data based on experience with mock submissions-view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee. Environ. Health Perspect. 2006, 114: 573-578.
21. Khor, T.O., Ibrahim, S., Kong, A.N. Toxicogenomics in drug discovery and drug development: potential applications and future challenges. Pharm. Res. 2006, 23: 1659-1664.
22. de Longueville, F., Bertholet, V., Remacle, J. DNA microarrays as a tool in toxicogenomics. Comb. Chem. High Through. Screen. 2004, 7: 207-211.
23. Hamadeh, H.K., Bushel, P.R., Jayadev, S., DiSorbo, O., Bennett, L., Li, L., Tennant, R., Stoll, R., Barrett, J.C., Piades, R.S., Blanchard, K., Afshari, C.A. Prediction of compound signature using high density gene expression profiling. Toxicol. Sci. 2002, 67: 232-240.
24. Hamadeh, H.K., Bushel, P.R., Jayadev, S., Martin, K., DiSorbo, O., Sieber, S., Bennett, L., Tennant, R., Stoll, R., Barrett, J.C., Blanchard, K., Paules, R.S., Afshari, C.A. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 2002, 67: 219-231.
25. Morgan, K.T. Gene expression analysis reveals chemical-specific profiles. Toxicol. Sci. 2002, 67: 155-156.
26. de Longueville, F., Surry, D., Meneses-Lorente, G., Bertholet, V., Talbot, V., Evrard, S., Chandelier, N., Pike, A., Worboys, P., Rasson, J.P., Le Bourdelles, B., Remacle, J. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem. Pharmacol. 2002, 64: 137-149.
27. Waring, J.F., Cavet, G., Jolly, R.A., McDowell, J., Dai, H., Ciurlionis, R., Zhang, C., Stoughton, R., Lum, P., Ferguson, A., Roberts, C.J., Ulrich, R.G. Development of a DNA microarray for toxicology based on hepatotoxin-regulated sequences. EHP Toxicogenom. 2003, 111: 53-60.
28. Waring, J.F., Gum, R., Morfitt, D., Jolly, R.A., Ciurlionis, R., Heindel, M., Gallenberg, L., Buratto, B., Ulrich, R.G. Identifying toxic mechanisms using DNA microarrays: evidence that an experimental inhibitor of cell adhesion molecule expression signals through the aryl hydrocarbon nuclear receptor. Toxicology 2002, 182: 537-550.
29. Yang, Y., Abel, S.J., Ciurlionis, R., Waring, J.F. Development of a toxicogenomics in vitro assay for the efficient characterization of compounds. Pharmacogenomics 2006, 7: 177-186.
30. Boverhof, D.R., Zacharewski, T.R. Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 2006, 89: 352-360.
31. Lord, P.G., Nie, A., McMillian, M. Application of genomics in preclinical drug safety evaluation. Basic Clin. Pharmacol. Toxicol. 2006, 98: 537-546.
32. Guerreiro, N., Staedtler, F., Grenet, O., Kehren, J., Chibout, S.D. Toxicogenomics in drug development. Toxicol. Pathol., 2003, 31: 471-479.
33. Lee, J., Richburg, J.H., Shipp, E.B., Meistrich, M.L., Boekelheide, K. The Fas system, a regulator of testicular germ cell apoptosis, is differentially up-regulated in Sertoli cell versus germ cell injury of the testis. Endocrinology 1999, 140: 852-858.
34. Richburg, J.H., Nanez, A., Williams, L.R., Embree, M.E., Boekelheide, K. Sensitivity of testicular germ cells to toxicant-induced apoptosis in gld mice that express a nonfunctional form of Fas ligand. Endocrinology 2000, 141: 787-793.
35. Mantovani, A., Maranghi, F. Risk assessment of chemicals potentially affecting male fertility. Contraception 2005, 72: 308-313.
36. Richburg, J.H., Johnson, K.J., Schoenfeld, H.A., Meistrich, M.L., Dix, D.J. Defining the cellular and molecular mechanisms of toxicant action in the testis. Toxicol. Lett. 2002, 135: 167-183.
37. Boess, F., Kamber, M., Romer, S., Gasser, R., Muller, D., Albertini, S., Suter, L. Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci. 2003, 73: 386-402.
38. Ruepp, S., Boess, F., Suter, L., de Vera, M.C., Steiner, G., Steele, T., Weiser, T., Albertini, S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 2005, 207: 161-170.
39. Li, A.P., Reith, M.K., Rasmussen, A., Gorski, J.C., Hall, S.D., Xu, L., Kaminski, D.L., Cheng, L.K. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 1997, 107: 17-30.
40. Ulrich, R.G., Bacon, J.A., Cramer, C.T., Peng, G.W., Petrella, D.K., Stryd, R.P., Sun, E.L. Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development. Toxicol. Lett. 1995, 83: 107-115.
41. Waring, J.F., Ciurlionis, R., Jolly, R.A., Heindel, M., Ulrich, R.G. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol. Lett. 2001, 120: 359-368.
42. Hong, Y., Muller, U.R., Lai, F. Discriminating two classes of toxicants through expression analysis of HepG2 cells with DNA arrays. Toxicol. In Vitro 2003, 17: 85-92.
43. Ulrich, R.G. The toxicogenomics of nuclear receptor agonists. Curr. Opin. Chem. Biol. 2003, 7: 505-510.
44. Cascorbi, I. Genetic basis of toxic reactions to drugs and chemicals. Toxicol. Lett. 2006; 162: 16-28.
45. Goetz, M.P., Erlichman, C., Windebank, A.J., Reid, J.M., Sloan, J.A., Atherton, P., Adjei, A.A., Rubin, J., Pitot, H., Galanis, E., Ames, M.M., Goldberg, R.M. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J. Clin. Oncol. 2003, 21: 3761-3769.
46. Goetz, M.P., Grothey, A. Developments in combination chemotherapy for colorectal cancer. Expert Rev. Anticancer Ther. 2004, 4: 627-637.
47. Heller, T., Kirchheiner, J., Armstrong, V.W., Luthe, H., Tzvetkov, M., Brockmoller, J., Oellerich, M. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther. Drug Monit. 2006, 28: 673-677.
48. Kier, L.D., Neft, R., Tang, L., Suizu, R., Cook, T., Onsurez, K., Tiegler, K., Sakai, Y., Ortiz, M., Nolan, T., Sankar, U., Li, A.P. Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat. Res. 2004, 549: 101-113.
49. Baken, K.A., Vandebriel, R.J., Pennings, J.L., Kleinjans, J.C., van Loveren, H. Toxicogenomics in the assessment of immunotoxicity. Methods 2007, 41: 132-141.
50. Ganter, B., Snyder, R.D., Halbert, D.N., Lee, M.D. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/ class-dependent effects using the DrugMatrix database. Pharmacogenomics 2006, 7: 1025-1044.
51. Lazarou, J., Pomeranz, B.H., Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279: 1200-1205.
52. Nelson, J.C. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol. Psychiatry 1999, 46: 1301-1308.
53. Lockhart, D.J., Dong, H., Byrne, M.C., Follettie, M.T., Gallo, M.V., Chee, M.S., Mittmann, M., Wang, C., Kobayashi, M., Horton, H., Brown, E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 1996, 14: 1675-1680.
54. Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J., Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., Reich, M., Hieŕonymus, H., Wei, G., Armstrong, S.A., Haggarty, S.J., Clemons, P.A., Wei, R., Carr, S.A., Lander, E.S., Golub, T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313: 1929-1935.
55. Gunther, E.C., Stone, D.J., Gerwien, R.W., Bento, P., Heyes, M.P. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc. Natl. Acad. Sci. U S A 2003, 100: 9608-9613.
56. Follettie, M.T., Ellis, D.K., Donaldson, D.D., Hill, A.A., Diesl, V., DeClercq, C., Sypek, J.P., Dorner, A.J., Wills-Karp, M. Gene expression analysis in a murine model of allergic asthma reveals overlapping disease and therapy dependent pathways in the lung. Pharmacogenomics J 2006, 6: 141-152.
57. Burczynski, M.E., Twine, N.C., Dukart, G., Marshall, B., Hidalgo, M., Stadler, W.M., Logan, T., Dutcher, J., Hudes, G., Trepicchio, W.L., Strahs, A., Immermann, F., Slonim, D.K., Domer, A.J. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin. Cancer. Res. 2005, 11: 1181-1189.
58. Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W.J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., Trepicchio, W.L., Broyl, A., Sonneveld, P., Shaughnessy, J.D. Jr., Bergsagel, P.L., Schenkein, D., Esseltine, D.L., Boral, A., Anderson, K.C. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007, 109: 3177-3188.
59. Burczynski, M.E., Domer, A.J. Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies. Pharmacogenomics 2006, 7: 187-202.
60. Veenstra, D.L., Higashi, M.K., Phillips, K.A. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharm.Sci. 2000, 2: E29.
61. Colburn, W.A. Biomarkers in drug discovery and development: from target identification through drug marketing. J. Clin. Pharmacol. 2003, 43: 329-341.